RxDoctor Payments Data

Rajakumari Swamy, MD

Internal Medicine · Grand Blanc, MINPI 1124044425

Payments from drug & device makers

$1,101in general payments, 2019–2025

Across 70 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$368
  • AstraZeneca$250
  • AbbVie$104
  • Cardiovascular Systems Inc.$85
  • Sanofi-aventis U.S. LLC$62
  • Abbott$57
  • plus $176 from 8 others

What the payments were for

  • Food & beverage$1,08799%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,101 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$355,941
Medicare patients
425
Services billed
8,631

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban401$401,465
OzempicSemaglutide158$219,846
TrulicityDulaglutide158$196,797
JanuviaSitagliptin Phosphate180$173,867
MounjaroTirzepatide137$169,638
FarxigaDapagliflozin Propanediol98$117,472
XareltoRivaroxaban100$108,791
Humira PenAdalimumab13$92,247
JardianceEmpagliflozin78$91,655
Trelegy ElliptaFluticasone/Umeclidin/Vilanter104$79,451
ProliaDenosumab39$63,246
Lantus SolostarInsulin Glargine,hum.Rec.Anlog199$34,430
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$22,681
Atorvastatin Calcium1,429$21,640
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$21,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid, Premarin$11$422,094443 claims
Lilly USA, LLCTrulicity, Mounjaro$20$366,435295 claims
Novo NordiskOzempic$26$219,846158 claims
AstraZenecaFarxiga, Breztri Aerosphere$250$138,987126 claims
Johnson & JohnsonXarelto$36$108,791100 claims
GSKTrelegy Ellipta$368$79,451104 claims
AmgenProlia$14$63,24639 claims
AbbVieCreon$104$6,70617 claims
Sanofi-aventis U.S. LLCLantus$62$6,37017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Grand Blanc

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →